Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.
about
Feline preleukemia: an animal model of human disease.Treatment of advanced malignancy with plasma perfused over staphylococcal protein ACell-mediated immunity against herpes simplex induction of cytotoxic T lymphocytesSuppressive effect of a chronic helminth infection, schistosomiasis mansoni, on the in vitro responses of spleen and lymph node cells to the T cell mitogens phytohemagglutinin and concanavalin AHuman tumour-associated and tumour-specific antigens: some concepts in relation to clinical oncologyNonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.Antigen-specific purification of blocking factors from sera of mice with chemically induced tumors.Immunological escape mechanism in spontaneously metastasizing mammary tumors.Rapid isolation of monoclonal antibodies specific for cell surface differentiation antigens.Role of circulating soluble immune complexes in diseaseThe clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatmentImmune complexes in human diseases: a reviewEffect of solubilized membrane antigens and tumour bearer serum on tumour growth in syngeneic hosts.Tumour-induced changes in murine lymphocyte profilesImmunopathology.Tumor immunity. An overviewInduction of resistance or enhancement to a transplantable murine plasmacytoma by transfer of non-immune leucocytes.Comparison of autochthonous and allogeneic breast-tumour cells in tests for lymphocyte immunity to human tumours.Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma.Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.Studies on the role of the host immune response in recovery from Friend virus leukemia. II. Cell-mediated immunityA stable form of delayed-type hypersensitivity.Adjuvant immunotherapy with BCG in squamous-cell bronchial carcinoma. Immune-reactivity in relation to immunostimulation (preliminary results in a controlled trial).The primary immune response of patients with different stages of squamous-cell bronchial carcinoma.Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammationDetection of immune complexes in acute rheumatic fever and their relationship to HLA-B5.Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.Isolation of circulating immune complexes using Raji cells. Separation of antigens from immune complexes and production of antiserumRole of circulating immune complexes in renal diseases.Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y.Analysis of heteroantisera to cells from human malignant effusions by immunofluorescence and protein A binding.Immune guided missiles.Microcirculation of the lymph node with metastasesCirculating immune complexes in patients with breast cancer.Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function.Selective suppression of the generation of anti-tumor L3T4+ but not of Lyt-2+ T cell-mediated immunity in the tumor-bearing state.
P2860
Q33398208-D98DF099-13EB-4879-B731-7A77D9907892Q33580697-1F8BA619-50EB-405C-8EF9-5BD4C1D14560Q33898013-FAD5FA04-76FE-486F-9128-22A02EDD1A53Q34393126-47C993E4-7F7C-49D9-8880-54F823721A47Q34538806-E3ABE66D-A082-4557-A058-5BF2B586D9B3Q34912810-F7BA8F1A-3AD4-4215-A8FA-CC7656887F47Q35058401-A8485932-EA4E-4129-80D5-606FFB846A27Q35073186-2ACFC15E-F683-471B-9C9D-0791AFCA35E4Q35611151-9D4968AE-367E-4E28-B549-DD98386BDD09Q35656929-96989DC3-800E-46A6-905E-4CC7183F2FFCQ35657649-F7524D4F-A735-4A1C-B79F-60623E85FE7BQ35863255-3E9F33A7-EFCB-4418-A529-F6DBEA1D1DE2Q36041211-4A7E6EA6-667C-436A-BBA6-9A88DE92383EQ36046997-3DEA24CC-FBFE-4699-8DDD-42D5A056B043Q36058579-A7D4B9A4-A4C5-48F0-829D-83DB4F491563Q36058893-4358B103-E734-4D5E-B269-C7918FABEEC8Q36068785-FB195161-D9EC-425B-AAF7-D4BC828CE1B4Q36069018-894D240C-1883-4618-9BE9-BE6144B928FCQ36078444-0416AF92-E3DA-4567-B2BB-63F48D4B4E3CQ36319582-C239797B-0C93-4152-81BB-E3DBF4342031Q36346369-34B2F06B-FF2F-4820-AC1D-AFA4DADE7364Q36358972-0F15B795-AE0A-4E62-BE82-3029BF991733Q36360223-813A15A6-98E5-472B-B533-B9A9D1235716Q36451984-A9B0F8E3-CB7D-46D6-861B-268D879EBCA8Q36453884-D94380D2-D765-495A-BA25-21DBFBFF6EA4Q36936462-7EFFCCC6-1103-4177-9A7D-DAE00045FC8EQ37019408-65A62104-920B-428B-B0B8-7C67C6585C73Q37044647-89B29D8A-2F54-493C-B00D-9BC54E5BADBEQ37054231-95111B6D-7147-4791-85F1-371570B88156Q37094347-94CE505F-9886-4A6F-A26D-99A255031BF1Q37599102-7B87CB14-EE9D-49E6-A8C8-BE7EBCE64CDDQ40845369-6A87C2CD-573E-4B89-8E27-A156E8E9B59FQ41433857-EF96CA20-ED67-4D96-9AEE-0796D8802682Q41839823-45AF9117-BE70-46FD-9510-581B4A218B85Q49958856-46B4AD04-7C3A-4544-81F0-0B3CBFB7AE4BQ55145161-95B429C8-832B-4C22-8203-1424EDF65431Q55220951-4C669CCB-AD8D-48CF-BFF2-0DEF7872538C
P2860
Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.
description
1974 nî lūn-bûn
@nan
1974年の論文
@ja
1974年論文
@yue
1974年論文
@zh-hant
1974年論文
@zh-hk
1974年論文
@zh-mo
1974年論文
@zh-tw
1974年论文
@wuu
1974年论文
@zh
1974年论文
@zh-cn
name
Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.
@en
Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.
@nl
type
label
Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.
@en
Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.
@nl
prefLabel
Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.
@en
Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.
@nl
P1476
Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens
@en
P2093
Hellström I
Hellström KE
P304
P577
1974-01-01T00:00:00Z